{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.6"},{"groupId":"OG002","value":"46.4"},{"groupId":"OG003","value":"36.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"509"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"125"},{"groupId":"OG003","value":"124"}],"units":"Participants"}],"title":"TEAEs related to Enzalutamide or Placebo"},{"categories":[{"measurements":[{"groupId":"OG001","value":"38.5"},{"groupId":"OG002","value":"54.4"},{"groupId":"OG003","value":"45.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"125"},{"groupId":"OG003","value":"124"}],"units":"Participants"}],"title":"TEAEs related to Abiraterone"},{"categories":[{"measurements":[{"groupId":"OG001","value":"7.7"},{"groupId":"OG002","value":"36.0"},{"groupId":"OG003","value":"32.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"125"},{"groupId":"OG003","value":"124"}],"units":"Participants"}],"title":"TEAEs related to Prednisone"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1"},{"groupId":"OG002","value":"7.2"},{"groupId":"OG003","value":"4.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"509"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"125"},{"groupId":"OG003","value":"124"}],"units":"Participants"}],"title":"SAEs related to Enzalutamide or Placebo"},{"categories":[{"measurements":[{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"7.2"},{"groupId":"OG003","value":"4.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"125"},{"groupId":"OG003","value":"124"}],"units":"Participants"}],"title":"SAEs related to Abiraterone"},{"categories":[{"measurements":[{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2.4"},{"groupId":"OG003","value":"4.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"125"},{"groupId":"OG003","value":"124"}],"units":"Participants"}],"title":"SAEs related to Prednisone"}],"denoms":[{"counts":[{"groupId":"OG000","value":"509"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"125"},{"groupId":"OG003","value":"124"}],"units":"Participants"}],"description":"Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state. Relatedness to study drug was assessed by the investigator.","groups":[{"description":"Participants who only received enzalutamide 160 mg as four 40 mg capsules, orally once daily in the study.","id":"OG000","title":"Enzalutamide 160 mg"},{"description":"Participants who received (after switching from enzalutamide), abiraterone 1000 mg as four 250 mg tablets, orally once daily and prednisone 10 mg administered as two 5 mg tablets, orally twice daily in the study.","id":"OG001","title":"Enzalutamide Crossing Over to Abiraterone + Prednisone"},{"description":"Participants who received enzalutamide 160 mg as four 40 mg capsules, orally once daily along with abiraterone 1000 mg as four 250-mg tablets, orally once daily and prednisone 5 mg tablet, orally twice daily in the study.","id":"OG002","title":"Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg"},{"description":"Participants who received placebo matched to enzalutamide as four 40 mg capsules, orally once daily along with abiraterone 1000 mg as four 250-mg tablets, orally once daily and prednisone 5 mg tablet, orally twice daily in the study.","id":"OG003","title":"Placebo+Abiraterone 1000mg+ Prednisone 10mg"}],"paramType":"NUMBER","populationDescription":"Safety population included all participants who received any amount of study drug. \"Number Analyzed\" signifies participants evaluable for the specified categories for respective arms.","reportingStatus":"POSTED","timeFrame":"Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (maximum of 99.4 months)","title":"Percentage of Participants With Treatment-Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"percentage of participants"}